In vitro colony studies in 87 patients with acute nonlymphoblastic leukemia. Prognostic value of colony-stimulating activity and colony-forming cells

Radiotoxicity of 67-gallium on myeloid leukemic blasts

Promising clinical results are obtained with radiolabeled antibodies in leukemia patients. 67Gallium (67Ga) is a radionuclide that accumulates in many malignant tissues without need for a monoclonal antibody. For this reason, the use of 67Ga as a therapeutic agent is appealing. In the present we study, we report data about the radiotoxicity of 67Ga on peripheral blast cells of 23 patients with acute myelogenous leukemia (AML) in vitro. Isolated blast cells were incubated for 4 days with 0.74 MBq/ml (20 microCi/ml), 1.48 MBq/ml (40 microCi/ml) or 2.96 MBq/ml (80 microCi/ml) 67Ga. Compared with non-irradiated control cells proliferation during incubation was almost abolished. Clonogenic survival was measured by a colony forming unit assay (CFU-assay). In 13 of the 23 patients (56%) sufficient colony growth was observed for evaluation. The mean clonogenic survival of blasts after incubation with 0.74 MBq/ml and 2.96 MBq/ml 67Ga was 22.5, 11.3 and 3.5%, respectively. In some cases colony growth was completely abolished after incubation with only 0.74 MBq/ml 67Ga. No correlation was found between cellular 67Ga-uptake, (micro)dosimetry and transferrin receptor density (CD-71) via which 67Ga enters the cell. In vitro the blasts received a dose of > 10 Gy in 9 of the 2.96 MBq/ml, in 3 of the 1.48 MBq/ml and in 2 of the 0.74 MBq/ml incubations. In one patient, even a radiation dose > 40 Gy was reached. Low dose rate irradiation is known to arrest cells in G2/M-phase of the cell cycle, but no such arrest was observed during incubation with 67Ga. Thus, 67Ga induces clonogenic cell death in leukemic blasts. Cellular uptake of 67Ga in vitro varies between patients and can be very high in some patients. The easy availability, low costs and absence of immunological problems warrant further investigation of the therapeutic potential of 67Ga in refractory or relapsed AML patients.

Myeloid progenitors in acute non-lymphocytic leukemia: prognostic value in remission

The prognostic value of in vitro cloning of bone marrow and blood cells was tested in 32 patients with acute non-lymphocytic leukemia (ANLL) at various stages of disease. Using placental conditioned medium (PCM) as a stimulus and panoptical staining methods for the analysis of colony morphology, four different growth types could be distinguished at presentation. Poor response to colony-stimulating activity (GM-CSF) in vitro seemed to be associated with poor survival. Probably due to low patient numbers, this association could not be proven statistically. During remission a progressive decrease of morphologically normal colonies was recognized in the bone marrow and peripheral blood. Thus by in vitro cloning methods the quality of remission could be substantiated.

Marrow culture studies in adult acute myeloid leukemia at diagnosis and during complete remission

We used the human placental conditioned medium stimulated single layer agar culture technique to study the in vitro growth of marrow cells from 62 adult patients with acute myeloid leukemia (AML). Bone marrow cells were cultured from 50 patients at the time of initial diagnosis, 19 patients in early remission and 20 patients during their full complete remission. Marrow cultures from untreated patients exhibited heterogeneous growth patterns ranging from complete growth failure to excessive microcluster formation. We classified the growth patterns into 4 groups: (1) Gr I: normal growth, (2) Gr II: no growth, (3) Gr III: decreased growth, (4) Gr IV: excessive growth of microclusters. At presentation, none had Gr I growth; Gr II growth was observed in 23; Gr III in 14 and Gr IV in 13. A predominance of no growth were seen in M1 and M3 subtypes, while Gr IV growth was more commonly observed in M2 or M4 subtype. We were unable to correlate the culture findings with age or white cell count. The present results not only indicated that AML at diagnosis was characterized by abnormal granulopoiesis but also demonstrated that leukemic progenitor cells were heterogeneous with different capacities to express their proliferating potential in vitro. Except few with decreased growth, the growth characteristics generally returned to normal with successful remission induction. Both Gr II and Gr IV growth patterns were not observed either in early remission or during full complete remission.